Overview

• The analysis followed 124 adults with primary insomnia enrolled in the UK Medical Cannabis Registry for up to 18 months.
• Participants reported higher Single-Item Sleep Quality scores at every follow-up and lower GAD-7 anxiety scores with statistical significance.
• Quality-of-life measures improved and many patients reported reduced pain alongside sleep and mood benefits.
• Adverse events were reported by 11 participants (8.9%) and were mostly mild, including fatigue, dry mouth, or insomnia, with no serious outcomes.
• The PLOS Mental Health paper notes its observational design, discloses author affiliations with Curaleaf Clinic, and calls for controlled trials given signs of possible tolerance over time.